Hempacco Co., Inc.
Hempacco Co., Inc. (HPCO) Stock Competitors & Peer Comparison
See (HPCO) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HPCO | $0.00 | +200.00% | 5.3K | N/A | -$4.70 | N/A |
| ZTS | $150.78 | -0.88% | 67.1B | 27.06 | $5.57 | +1.28% |
| TAK | $14.40 | -0.55% | 45.2B | 62.24 | $0.23 | +4.12% |
| HLN | $9.82 | -0.66% | 43.7B | 22.55 | $0.43 | +1.74% |
| TEVA | $16.50 | -0.24% | 18.9B | -14.36 | -$1.15 | N/A |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| NBIX | $134.44 | +1.74% | 13.2B | 45.33 | $2.95 | N/A |
| RDY | $14.74 | +0.48% | 12.3B | 18.63 | $0.79 | +0.50% |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| VTRS | $9.16 | -2.62% | 10.9B | -2.91 | -$3.18 | +5.19% |
Stock Comparison
HPCO vs ZTS Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, ZTS has a market cap of 67.1B. Regarding current trading prices, HPCO is priced at $0.00, while ZTS trades at $150.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas ZTS's P/E ratio is 27.06. In terms of profitability, HPCO's ROE is -3.60%, compared to ZTS's ROE of +0.51%. Regarding short-term risk, HPCO is less volatile compared to ZTS. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check ZTS's competition here
HPCO vs TAK Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, TAK has a market cap of 45.2B. Regarding current trading prices, HPCO is priced at $0.00, while TAK trades at $14.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas TAK's P/E ratio is 62.24. In terms of profitability, HPCO's ROE is -3.60%, compared to TAK's ROE of +0.04%. Regarding short-term risk, HPCO is less volatile compared to TAK. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check TAK's competition here
HPCO vs HLN Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, HLN has a market cap of 43.7B. Regarding current trading prices, HPCO is priced at $0.00, while HLN trades at $9.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas HLN's P/E ratio is 22.55. In terms of profitability, HPCO's ROE is -3.60%, compared to HLN's ROE of +0.09%. Regarding short-term risk, HPCO is less volatile compared to HLN. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check HLN's competition here
HPCO vs TEVA Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, TEVA has a market cap of 18.9B. Regarding current trading prices, HPCO is priced at $0.00, while TEVA trades at $16.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas TEVA's P/E ratio is -14.36. In terms of profitability, HPCO's ROE is -3.60%, compared to TEVA's ROE of -0.21%. Regarding short-term risk, HPCO is less volatile compared to TEVA. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check TEVA's competition here
HPCO vs ITCI Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, HPCO is priced at $0.00, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas ITCI's P/E ratio is -180.64. In terms of profitability, HPCO's ROE is -3.60%, compared to ITCI's ROE of -0.07%. Regarding short-term risk, HPCO and ITCI have similar daily volatility (0.00).Check ITCI's competition here
HPCO vs NBIX Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, NBIX has a market cap of 13.2B. Regarding current trading prices, HPCO is priced at $0.00, while NBIX trades at $134.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas NBIX's P/E ratio is 45.33. In terms of profitability, HPCO's ROE is -3.60%, compared to NBIX's ROE of +0.12%. Regarding short-term risk, HPCO is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check NBIX's competition here
HPCO vs RDY Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, RDY has a market cap of 12.3B. Regarding current trading prices, HPCO is priced at $0.00, while RDY trades at $14.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas RDY's P/E ratio is 18.63. In terms of profitability, HPCO's ROE is -3.60%, compared to RDY's ROE of +0.17%. Regarding short-term risk, HPCO is less volatile compared to RDY. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check RDY's competition here
HPCO vs CTLT Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, HPCO is priced at $0.00, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas CTLT's P/E ratio is -27.84. In terms of profitability, HPCO's ROE is -3.60%, compared to CTLT's ROE of -0.11%. Regarding short-term risk, HPCO is less volatile compared to CTLT. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check CTLT's competition here
HPCO vs VTRS Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, VTRS has a market cap of 10.9B. Regarding current trading prices, HPCO is priced at $0.00, while VTRS trades at $9.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas VTRS's P/E ratio is -2.91. In terms of profitability, HPCO's ROE is -3.60%, compared to VTRS's ROE of -0.21%. Regarding short-term risk, HPCO is less volatile compared to VTRS. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check VTRS's competition here
HPCO vs ELAN Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, ELAN has a market cap of 7.2B. Regarding current trading prices, HPCO is priced at $0.00, while ELAN trades at $14.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas ELAN's P/E ratio is 19.44. In terms of profitability, HPCO's ROE is -3.60%, compared to ELAN's ROE of +0.06%. Regarding short-term risk, HPCO is less volatile compared to ELAN. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check ELAN's competition here
HPCO vs RGC Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, RGC has a market cap of 6.8B. Regarding current trading prices, HPCO is priced at $0.00, while RGC trades at $13.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas RGC's P/E ratio is -1380.00. In terms of profitability, HPCO's ROE is -3.60%, compared to RGC's ROE of -0.50%. Regarding short-term risk, HPCO is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check RGC's competition here
HPCO vs LNTH Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, LNTH has a market cap of 5B. Regarding current trading prices, HPCO is priced at $0.00, while LNTH trades at $72.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas LNTH's P/E ratio is 20.63. In terms of profitability, HPCO's ROE is -3.60%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, HPCO is less volatile compared to LNTH. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check LNTH's competition here
HPCO vs PRGO Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, PRGO has a market cap of 3.9B. Regarding current trading prices, HPCO is priced at $0.00, while PRGO trades at $28.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas PRGO's P/E ratio is -23.44. In terms of profitability, HPCO's ROE is -3.60%, compared to PRGO's ROE of -0.04%. Regarding short-term risk, HPCO is less volatile compared to PRGO. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check PRGO's competition here
HPCO vs HCM Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, HCM has a market cap of 3.2B. Regarding current trading prices, HPCO is priced at $0.00, while HCM trades at $19.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas HCM's P/E ratio is 89.90. In terms of profitability, HPCO's ROE is -3.60%, compared to HCM's ROE of +0.05%. Regarding short-term risk, HPCO is less volatile compared to HCM. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check HCM's competition here
HPCO vs ALVO Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, ALVO has a market cap of 3B. Regarding current trading prices, HPCO is priced at $0.00, while ALVO trades at $9.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas ALVO's P/E ratio is 26.51. In terms of profitability, HPCO's ROE is -3.60%, compared to ALVO's ROE of -0.23%. Regarding short-term risk, HPCO is less volatile compared to ALVO. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check ALVO's competition here
HPCO vs AMRX Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, AMRX has a market cap of 2.6B. Regarding current trading prices, HPCO is priced at $0.00, while AMRX trades at $8.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas AMRX's P/E ratio is -204.37. In terms of profitability, HPCO's ROE is -3.60%, compared to AMRX's ROE of -0.07%. Regarding short-term risk, HPCO is less volatile compared to AMRX. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check AMRX's competition here
HPCO vs BHC Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, BHC has a market cap of 2.5B. Regarding current trading prices, HPCO is priced at $0.00, while BHC trades at $6.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas BHC's P/E ratio is -57.42. In terms of profitability, HPCO's ROE is -3.60%, compared to BHC's ROE of +0.05%. Regarding short-term risk, HPCO is less volatile compared to BHC. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check BHC's competition here
HPCO vs DCPH Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, HPCO is priced at $0.00, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas DCPH's P/E ratio is -11.58. In terms of profitability, HPCO's ROE is -3.60%, compared to DCPH's ROE of -0.28%. Regarding short-term risk, HPCO is less volatile compared to DCPH. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check DCPH's competition here
HPCO vs ALVOW Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, ALVOW has a market cap of 2.1B. Regarding current trading prices, HPCO is priced at $0.00, while ALVOW trades at $2.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas ALVOW's P/E ratio is N/A. In terms of profitability, HPCO's ROE is -3.60%, compared to ALVOW's ROE of -0.23%. Regarding short-term risk, HPCO is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check ALVOW's competition here
HPCO vs INDV Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, INDV has a market cap of 2.1B. Regarding current trading prices, HPCO is priced at $0.00, while INDV trades at $17.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas INDV's P/E ratio is -341.80. In terms of profitability, HPCO's ROE is -3.60%, compared to INDV's ROE of -0.01%. Regarding short-term risk, HPCO is less volatile compared to INDV. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check INDV's competition here
HPCO vs BGM Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, BGM has a market cap of 2B. Regarding current trading prices, HPCO is priced at $0.00, while BGM trades at $9.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas BGM's P/E ratio is -34.62. In terms of profitability, HPCO's ROE is -3.60%, compared to BGM's ROE of -0.03%. Regarding short-term risk, HPCO is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check BGM's competition here
HPCO vs EMBCV Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, HPCO is priced at $0.00, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas EMBCV's P/E ratio is N/A. In terms of profitability, HPCO's ROE is -3.60%, compared to EMBCV's ROE of -0.07%. Regarding short-term risk, HPCO is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check EMBCV's competition here
HPCO vs SUPN Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, SUPN has a market cap of 1.9B. Regarding current trading prices, HPCO is priced at $0.00, while SUPN trades at $33.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas SUPN's P/E ratio is 30.10. In terms of profitability, HPCO's ROE is -3.60%, compared to SUPN's ROE of +0.06%. Regarding short-term risk, HPCO is less volatile compared to SUPN. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check SUPN's competition here
HPCO vs TARO Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, HPCO is priced at $0.00, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas TARO's P/E ratio is 30.05. In terms of profitability, HPCO's ROE is -3.60%, compared to TARO's ROE of +0.02%. Regarding short-term risk, HPCO is less volatile compared to TARO. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check TARO's competition here
HPCO vs EVO Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, EVO has a market cap of 1.5B. Regarding current trading prices, HPCO is priced at $0.00, while EVO trades at $4.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas EVO's P/E ratio is -6.17. In terms of profitability, HPCO's ROE is -3.60%, compared to EVO's ROE of -0.22%. Regarding short-term risk, HPCO is less volatile compared to EVO. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check EVO's competition here
HPCO vs ANIP Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, ANIP has a market cap of 1.4B. Regarding current trading prices, HPCO is priced at $0.00, while ANIP trades at $66.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas ANIP's P/E ratio is -56.29. In terms of profitability, HPCO's ROE is -3.60%, compared to ANIP's ROE of -0.05%. Regarding short-term risk, HPCO is less volatile compared to ANIP. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check ANIP's competition here
HPCO vs DVAX Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, DVAX has a market cap of 1.4B. Regarding current trading prices, HPCO is priced at $0.00, while DVAX trades at $11.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas DVAX's P/E ratio is -22.58. In terms of profitability, HPCO's ROE is -3.60%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, HPCO is less volatile compared to DVAX. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check DVAX's competition here
HPCO vs HROW Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, HROW has a market cap of 1.3B. Regarding current trading prices, HPCO is priced at $0.00, while HROW trades at $34.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas HROW's P/E ratio is -57.15. In terms of profitability, HPCO's ROE is -3.60%, compared to HROW's ROE of -0.36%. Regarding short-term risk, HPCO is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check HROW's competition here
HPCO vs FLXN Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, FLXN has a market cap of 1.3B. Regarding current trading prices, HPCO is priced at $0.00, while FLXN trades at $25.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas FLXN's P/E ratio is N/A. In terms of profitability, HPCO's ROE is -3.60%, compared to FLXN's ROE of +6.19%. Regarding short-term risk, HPCO and FLXN have similar daily volatility (0.00).Check FLXN's competition here
HPCO vs PAHC Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, PAHC has a market cap of 1.2B. Regarding current trading prices, HPCO is priced at $0.00, while PAHC trades at $28.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas PAHC's P/E ratio is 37.08. In terms of profitability, HPCO's ROE is -3.60%, compared to PAHC's ROE of +0.12%. Regarding short-term risk, HPCO is less volatile compared to PAHC. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check PAHC's competition here
HPCO vs AVDL Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, AVDL has a market cap of 1.1B. Regarding current trading prices, HPCO is priced at $0.00, while AVDL trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas AVDL's P/E ratio is -41.69. In terms of profitability, HPCO's ROE is -3.60%, compared to AVDL's ROE of -0.36%. Regarding short-term risk, HPCO is less volatile compared to AVDL. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check AVDL's competition here
HPCO vs AMPH Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, AMPH has a market cap of 1B. Regarding current trading prices, HPCO is priced at $0.00, while AMPH trades at $21.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas AMPH's P/E ratio is 8.06. In terms of profitability, HPCO's ROE is -3.60%, compared to AMPH's ROE of +0.19%. Regarding short-term risk, HPCO is less volatile compared to AMPH. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check AMPH's competition here
HPCO vs PCRX Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, HPCO is priced at $0.00, while PCRX trades at $21.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas PCRX's P/E ratio is -9.84. In terms of profitability, HPCO's ROE is -3.60%, compared to PCRX's ROE of -0.13%. Regarding short-term risk, HPCO is less volatile compared to PCRX. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check PCRX's competition here
HPCO vs COLL Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, COLL has a market cap of 1B. Regarding current trading prices, HPCO is priced at $0.00, while COLL trades at $31.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas COLL's P/E ratio is 25.70. In terms of profitability, HPCO's ROE is -3.60%, compared to COLL's ROE of +0.19%. Regarding short-term risk, HPCO is less volatile compared to COLL. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check COLL's competition here
HPCO vs PETQ Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, HPCO is priced at $0.00, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas PETQ's P/E ratio is 83.73. In terms of profitability, HPCO's ROE is -3.60%, compared to PETQ's ROE of +0.05%. Regarding short-term risk, HPCO is less volatile compared to PETQ. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check PETQ's competition here
HPCO vs CRON Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, CRON has a market cap of 794M. Regarding current trading prices, HPCO is priced at $0.00, while CRON trades at $2.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas CRON's P/E ratio is 14.71. In terms of profitability, HPCO's ROE is -3.60%, compared to CRON's ROE of +0.05%. Regarding short-term risk, HPCO is less volatile compared to CRON. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check CRON's competition here
HPCO vs TLRY Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, TLRY has a market cap of 726.4M. Regarding current trading prices, HPCO is priced at $0.00, while TLRY trades at $0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas TLRY's P/E ratio is -0.64. In terms of profitability, HPCO's ROE is -3.60%, compared to TLRY's ROE of -0.29%. Regarding short-term risk, HPCO is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check TLRY's competition here
HPCO vs EMBC Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, EMBC has a market cap of 662.2M. Regarding current trading prices, HPCO is priced at $0.00, while EMBC trades at $11.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas EMBC's P/E ratio is 12.73. In terms of profitability, HPCO's ROE is -3.60%, compared to EMBC's ROE of -0.07%. Regarding short-term risk, HPCO is less volatile compared to EMBC. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check EMBC's competition here
HPCO vs ORGO Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, ORGO has a market cap of 636.8M. Regarding current trading prices, HPCO is priced at $0.00, while ORGO trades at $4.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas ORGO's P/E ratio is -31.37. In terms of profitability, HPCO's ROE is -3.60%, compared to ORGO's ROE of -0.06%. Regarding short-term risk, HPCO is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check ORGO's competition here
HPCO vs EOLS Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, EOLS has a market cap of 598.3M. Regarding current trading prices, HPCO is priced at $0.00, while EOLS trades at $9.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas EOLS's P/E ratio is -10.43. In terms of profitability, HPCO's ROE is -3.60%, compared to EOLS's ROE of -9.32%. Regarding short-term risk, HPCO is less volatile compared to EOLS. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check EOLS's competition here
HPCO vs BDSI Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, HPCO is priced at $0.00, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas BDSI's P/E ratio is 6.82. In terms of profitability, HPCO's ROE is -3.60%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, HPCO is less volatile compared to BDSI. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check BDSI's competition here
HPCO vs SIGA Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, SIGA has a market cap of 515.1M. Regarding current trading prices, HPCO is priced at $0.00, while SIGA trades at $7.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas SIGA's P/E ratio is 10.76. In terms of profitability, HPCO's ROE is -3.60%, compared to SIGA's ROE of +0.25%. Regarding short-term risk, HPCO is less volatile compared to SIGA. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check SIGA's competition here
HPCO vs KMDA Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, KMDA has a market cap of 441.6M. Regarding current trading prices, HPCO is priced at $0.00, while KMDA trades at $7.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas KMDA's P/E ratio is 27.43. In terms of profitability, HPCO's ROE is -3.60%, compared to KMDA's ROE of +0.06%. Regarding short-term risk, HPCO is less volatile compared to KMDA. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check KMDA's competition here
HPCO vs AQST Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, AQST has a market cap of 397.3M. Regarding current trading prices, HPCO is priced at $0.00, while AQST trades at $3.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas AQST's P/E ratio is -6.90. In terms of profitability, HPCO's ROE is -3.60%, compared to AQST's ROE of +1.07%. Regarding short-term risk, HPCO is less volatile compared to AQST. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check AQST's competition here
HPCO vs SNDL Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, SNDL has a market cap of 386M. Regarding current trading prices, HPCO is priced at $0.00, while SNDL trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas SNDL's P/E ratio is -5.00. In terms of profitability, HPCO's ROE is -3.60%, compared to SNDL's ROE of -0.09%. Regarding short-term risk, HPCO is less volatile compared to SNDL. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check SNDL's competition here
HPCO vs EBS Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, EBS has a market cap of 367.7M. Regarding current trading prices, HPCO is priced at $0.00, while EBS trades at $6.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas EBS's P/E ratio is -2.63. In terms of profitability, HPCO's ROE is -3.60%, compared to EBS's ROE of -0.27%. Regarding short-term risk, HPCO is less volatile compared to EBS. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check EBS's competition here
HPCO vs ESPR Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, ESPR has a market cap of 315.1M. Regarding current trading prices, HPCO is priced at $0.00, while ESPR trades at $1.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas ESPR's P/E ratio is -1.87. In terms of profitability, HPCO's ROE is -3.60%, compared to ESPR's ROE of +0.40%. Regarding short-term risk, HPCO is less volatile compared to ESPR. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check ESPR's competition here
HPCO vs ALIM Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, HPCO is priced at $0.00, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas ALIM's P/E ratio is 5.28. In terms of profitability, HPCO's ROE is -3.60%, compared to ALIM's ROE of -0.32%. Regarding short-term risk, HPCO is less volatile compared to ALIM. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check ALIM's competition here
HPCO vs TKNO Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, TKNO has a market cap of 274.7M. Regarding current trading prices, HPCO is priced at $0.00, while TKNO trades at $5.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas TKNO's P/E ratio is -11.17. In terms of profitability, HPCO's ROE is -3.60%, compared to TKNO's ROE of -0.28%. Regarding short-term risk, HPCO is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check TKNO's competition here
HPCO vs ZYBT Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, ZYBT has a market cap of 272.5M. Regarding current trading prices, HPCO is priced at $0.00, while ZYBT trades at $5.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas ZYBT's P/E ratio is 191.67. In terms of profitability, HPCO's ROE is -3.60%, compared to ZYBT's ROE of +0.11%. Regarding short-term risk, HPCO is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check ZYBT's competition here
HPCO vs LFCR Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, LFCR has a market cap of 271.4M. Regarding current trading prices, HPCO is priced at $0.00, while LFCR trades at $7.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas LFCR's P/E ratio is -4.99. In terms of profitability, HPCO's ROE is -3.60%, compared to LFCR's ROE of -2.64%. Regarding short-term risk, HPCO is less volatile compared to LFCR. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check LFCR's competition here
HPCO vs ACB Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, ACB has a market cap of 269.4M. Regarding current trading prices, HPCO is priced at $0.00, while ACB trades at $4.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas ACB's P/E ratio is 21.77. In terms of profitability, HPCO's ROE is -3.60%, compared to ACB's ROE of +0.00%. Regarding short-term risk, HPCO is less volatile compared to ACB. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check ACB's competition here
HPCO vs LNDC Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, HPCO is priced at $0.00, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas LNDC's P/E ratio is -4.04. In terms of profitability, HPCO's ROE is -3.60%, compared to LNDC's ROE of +2.28%. Regarding short-term risk, HPCO is less volatile compared to LNDC. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check LNDC's competition here
HPCO vs TYHT Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, HPCO is priced at $0.00, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas TYHT's P/E ratio is -1.61. In terms of profitability, HPCO's ROE is -3.60%, compared to TYHT's ROE of -1.41%. Regarding short-term risk, HPCO is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check TYHT's competition here
HPCO vs CGC Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, CGC has a market cap of 226.4M. Regarding current trading prices, HPCO is priced at $0.00, while CGC trades at $1.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas CGC's P/E ratio is -0.26. In terms of profitability, HPCO's ROE is -3.60%, compared to CGC's ROE of -1.13%. Regarding short-term risk, HPCO is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check CGC's competition here
HPCO vs OGI Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, OGI has a market cap of 198.1M. Regarding current trading prices, HPCO is priced at $0.00, while OGI trades at $1.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas OGI's P/E ratio is 11.38. In terms of profitability, HPCO's ROE is -3.60%, compared to OGI's ROE of +0.05%. Regarding short-term risk, HPCO is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check OGI's competition here
HPCO vs SXTC Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, SXTC has a market cap of 181M. Regarding current trading prices, HPCO is priced at $0.00, while SXTC trades at $1.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas SXTC's P/E ratio is 0.01. In terms of profitability, HPCO's ROE is -3.60%, compared to SXTC's ROE of +0.47%. Regarding short-term risk, HPCO is less volatile compared to SXTC. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check SXTC's competition here
HPCO vs DERM Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, DERM has a market cap of 178.9M. Regarding current trading prices, HPCO is priced at $0.00, while DERM trades at $7.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas DERM's P/E ratio is -20.76. In terms of profitability, HPCO's ROE is -3.60%, compared to DERM's ROE of -0.52%. Regarding short-term risk, HPCO is less volatile compared to DERM. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check DERM's competition here
HPCO vs REPH Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, HPCO is priced at $0.00, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas REPH's P/E ratio is -8.04. In terms of profitability, HPCO's ROE is -3.60%, compared to REPH's ROE of -0.22%. Regarding short-term risk, HPCO is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check REPH's competition here
HPCO vs BIOA Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, BIOA has a market cap of 162.4M. Regarding current trading prices, HPCO is priced at $0.00, while BIOA trades at $4.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas BIOA's P/E ratio is -2.29. In terms of profitability, HPCO's ROE is -3.60%, compared to BIOA's ROE of -0.38%. Regarding short-term risk, HPCO is less volatile compared to BIOA. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check BIOA's competition here
HPCO vs THTX Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, THTX has a market cap of 145.3M. Regarding current trading prices, HPCO is priced at $0.00, while THTX trades at $3.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas THTX's P/E ratio is -16.63. In terms of profitability, HPCO's ROE is -3.60%, compared to THTX's ROE of +0.38%. Regarding short-term risk, HPCO is less volatile compared to THTX. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check THTX's competition here
HPCO vs IRWD Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, IRWD has a market cap of 129.3M. Regarding current trading prices, HPCO is priced at $0.00, while IRWD trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas IRWD's P/E ratio is -4.20. In terms of profitability, HPCO's ROE is -3.60%, compared to IRWD's ROE of +0.10%. Regarding short-term risk, HPCO is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check IRWD's competition here
HPCO vs CRDL Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, CRDL has a market cap of 126.5M. Regarding current trading prices, HPCO is priced at $0.00, while CRDL trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas CRDL's P/E ratio is -4.37. In terms of profitability, HPCO's ROE is -3.60%, compared to CRDL's ROE of -2.10%. Regarding short-term risk, HPCO is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check CRDL's competition here
HPCO vs SCTL Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, HPCO is priced at $0.00, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas SCTL's P/E ratio is -7.86. In terms of profitability, HPCO's ROE is -3.60%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, HPCO is less volatile compared to SCTL. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check SCTL's competition here
HPCO vs PROC Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, PROC has a market cap of 114M. Regarding current trading prices, HPCO is priced at $0.00, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas PROC's P/E ratio is 1.53. In terms of profitability, HPCO's ROE is -3.60%, compared to PROC's ROE of -2.22%. Regarding short-term risk, HPCO is less volatile compared to PROC. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check PROC's competition here
HPCO vs IXHL Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, IXHL has a market cap of 111.5M. Regarding current trading prices, HPCO is priced at $0.00, while IXHL trades at $1.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas IXHL's P/E ratio is -0.97. In terms of profitability, HPCO's ROE is -3.60%, compared to IXHL's ROE of -2.03%. Regarding short-term risk, HPCO is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check IXHL's competition here
HPCO vs OPTN Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, HPCO is priced at $0.00, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas OPTN's P/E ratio is -4.42. In terms of profitability, HPCO's ROE is -3.60%, compared to OPTN's ROE of +0.64%. Regarding short-term risk, HPCO and OPTN have similar daily volatility (0.00).Check OPTN's competition here
HPCO vs ZOM Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, HPCO is priced at $0.00, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas ZOM's P/E ratio is -1.62. In terms of profitability, HPCO's ROE is -3.60%, compared to ZOM's ROE of -0.55%. Regarding short-term risk, HPCO is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check ZOM's competition here
HPCO vs GRVI Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, HPCO is priced at $0.00, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas GRVI's P/E ratio is 26.05. In terms of profitability, HPCO's ROE is -3.60%, compared to GRVI's ROE of +0.28%. Regarding short-term risk, HPCO is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check GRVI's competition here
HPCO vs QNTM Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, QNTM has a market cap of 85.2M. Regarding current trading prices, HPCO is priced at $0.00, while QNTM trades at $22.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas QNTM's P/E ratio is -1.88. In terms of profitability, HPCO's ROE is -3.60%, compared to QNTM's ROE of -1.88%. Regarding short-term risk, HPCO is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check QNTM's competition here
HPCO vs INCR Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, INCR has a market cap of 82.3M. Regarding current trading prices, HPCO is priced at $0.00, while INCR trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas INCR's P/E ratio is -3.36. In terms of profitability, HPCO's ROE is -3.60%, compared to INCR's ROE of -0.07%. Regarding short-term risk, HPCO is less volatile compared to INCR. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check INCR's competition here
HPCO vs ZYNE Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, HPCO is priced at $0.00, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, HPCO's ROE is -3.60%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, HPCO is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check ZYNE's competition here
HPCO vs ASRT Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, ASRT has a market cap of 69.6M. Regarding current trading prices, HPCO is priced at $0.00, while ASRT trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas ASRT's P/E ratio is -2.27. In terms of profitability, HPCO's ROE is -3.60%, compared to ASRT's ROE of -0.24%. Regarding short-term risk, HPCO is less volatile compared to ASRT. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check ASRT's competition here
HPCO vs SSIC Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, HPCO is priced at $0.00, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas SSIC's P/E ratio is 11.93. In terms of profitability, HPCO's ROE is -3.60%, compared to SSIC's ROE of +0.09%. Regarding short-term risk, HPCO is less volatile compared to SSIC. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check SSIC's competition here
HPCO vs VLNS Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, HPCO is priced at $0.00, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas VLNS's P/E ratio is -1.03. In terms of profitability, HPCO's ROE is -3.60%, compared to VLNS's ROE of N/A. Regarding short-term risk, HPCO is less volatile compared to VLNS. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check VLNS's competition here
HPCO vs CPIX Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, CPIX has a market cap of 52.1M. Regarding current trading prices, HPCO is priced at $0.00, while CPIX trades at $3.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas CPIX's P/E ratio is -14.50. In terms of profitability, HPCO's ROE is -3.60%, compared to CPIX's ROE of -0.13%. Regarding short-term risk, HPCO is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check CPIX's competition here
HPCO vs KALA Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, KALA has a market cap of 51.2M. Regarding current trading prices, HPCO is priced at $0.00, while KALA trades at $8.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas KALA's P/E ratio is -1.08. In terms of profitability, HPCO's ROE is -3.60%, compared to KALA's ROE of -3.69%. Regarding short-term risk, HPCO is less volatile compared to KALA. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check KALA's competition here
HPCO vs JUPW Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, HPCO is priced at $0.00, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas JUPW's P/E ratio is -2.41. In terms of profitability, HPCO's ROE is -3.60%, compared to JUPW's ROE of -9.40%. Regarding short-term risk, HPCO is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check JUPW's competition here
HPCO vs EGRX Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, EGRX has a market cap of 40.9M. Regarding current trading prices, HPCO is priced at $0.00, while EGRX trades at $3.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas EGRX's P/E ratio is 3.71. In terms of profitability, HPCO's ROE is -3.60%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, HPCO and EGRX have similar daily volatility (0.00).Check EGRX's competition here
HPCO vs QLI Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, HPCO is priced at $0.00, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas QLI's P/E ratio is -4.92. In terms of profitability, HPCO's ROE is -3.60%, compared to QLI's ROE of -0.16%. Regarding short-term risk, HPCO and QLI have similar daily volatility (0.00).Check QLI's competition here
HPCO vs RMTI Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, RMTI has a market cap of 35.2M. Regarding current trading prices, HPCO is priced at $0.00, while RMTI trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas RMTI's P/E ratio is -103.00. In terms of profitability, HPCO's ROE is -3.60%, compared to RMTI's ROE of -0.01%. Regarding short-term risk, HPCO is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check RMTI's competition here
HPCO vs HEXO Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, HPCO is priced at $0.00, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas HEXO's P/E ratio is -0.26. In terms of profitability, HPCO's ROE is -3.60%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, HPCO is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check HEXO's competition here
HPCO vs SCYX Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, SCYX has a market cap of 28.6M. Regarding current trading prices, HPCO is priced at $0.00, while SCYX trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas SCYX's P/E ratio is -1.31. In terms of profitability, HPCO's ROE is -3.60%, compared to SCYX's ROE of -0.48%. Regarding short-term risk, HPCO is less volatile compared to SCYX. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check SCYX's competition here
HPCO vs CYTH Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, HPCO is priced at $0.00, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas CYTH's P/E ratio is -0.80. In terms of profitability, HPCO's ROE is -3.60%, compared to CYTH's ROE of +7.50%. Regarding short-term risk, HPCO and CYTH have similar daily volatility (0.00).Check CYTH's competition here
HPCO vs COSM Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, COSM has a market cap of 20.5M. Regarding current trading prices, HPCO is priced at $0.00, while COSM trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas COSM's P/E ratio is -0.64. In terms of profitability, HPCO's ROE is -3.60%, compared to COSM's ROE of -0.51%. Regarding short-term risk, HPCO is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check COSM's competition here
HPCO vs GELS Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, GELS has a market cap of 18.5M. Regarding current trading prices, HPCO is priced at $0.00, while GELS trades at $1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas GELS's P/E ratio is -5.26. In terms of profitability, HPCO's ROE is -3.60%, compared to GELS's ROE of -0.07%. Regarding short-term risk, HPCO is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check GELS's competition here
HPCO vs PRPH Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, PRPH has a market cap of 18.4M. Regarding current trading prices, HPCO is priced at $0.00, while PRPH trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas PRPH's P/E ratio is -0.20. In terms of profitability, HPCO's ROE is -3.60%, compared to PRPH's ROE of -1.65%. Regarding short-term risk, HPCO is less volatile compared to PRPH. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check PRPH's competition here
HPCO vs DRRX Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, DRRX has a market cap of 17.2M. Regarding current trading prices, HPCO is priced at $0.00, while DRRX trades at $1.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas DRRX's P/E ratio is -1.15. In terms of profitability, HPCO's ROE is -3.60%, compared to DRRX's ROE of -0.93%. Regarding short-term risk, HPCO is less volatile compared to DRRX. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check DRRX's competition here
HPCO vs AYTU Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, AYTU has a market cap of 16.2M. Regarding current trading prices, HPCO is priced at $0.00, while AYTU trades at $2.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas AYTU's P/E ratio is -1.77. In terms of profitability, HPCO's ROE is -3.60%, compared to AYTU's ROE of +0.05%. Regarding short-term risk, HPCO is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check AYTU's competition here
HPCO vs ACRX Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, HPCO is priced at $0.00, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas ACRX's P/E ratio is -0.31. In terms of profitability, HPCO's ROE is -3.60%, compared to ACRX's ROE of -2.49%. Regarding short-term risk, HPCO is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check ACRX's competition here
HPCO vs FLGC Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, FLGC has a market cap of 13.7M. Regarding current trading prices, HPCO is priced at $0.00, while FLGC trades at $0.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas FLGC's P/E ratio is -0.63. In terms of profitability, HPCO's ROE is -3.60%, compared to FLGC's ROE of -2.55%. Regarding short-term risk, HPCO is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check FLGC's competition here
HPCO vs TXMD Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, TXMD has a market cap of 13.5M. Regarding current trading prices, HPCO is priced at $0.00, while TXMD trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas TXMD's P/E ratio is -6.16. In terms of profitability, HPCO's ROE is -3.60%, compared to TXMD's ROE of -0.08%. Regarding short-term risk, HPCO is less volatile compared to TXMD. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check TXMD's competition here
HPCO vs BFRI Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, BFRI has a market cap of 10.8M. Regarding current trading prices, HPCO is priced at $0.00, while BFRI trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas BFRI's P/E ratio is -1.32. In terms of profitability, HPCO's ROE is -3.60%, compared to BFRI's ROE of -2.16%. Regarding short-term risk, HPCO is less volatile compared to BFRI. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check BFRI's competition here
HPCO vs BFRIW Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, BFRIW has a market cap of 10.8M. Regarding current trading prices, HPCO is priced at $0.00, while BFRIW trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas BFRIW's P/E ratio is -0.15. In terms of profitability, HPCO's ROE is -3.60%, compared to BFRIW's ROE of -2.16%. Regarding short-term risk, HPCO is less volatile compared to BFRIW. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check BFRIW's competition here
HPCO vs AGRX Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, HPCO is priced at $0.00, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas AGRX's P/E ratio is -0.89. In terms of profitability, HPCO's ROE is -3.60%, compared to AGRX's ROE of +0.93%. Regarding short-term risk, HPCO is less volatile compared to AGRX. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check AGRX's competition here
HPCO vs TLPH Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, TLPH has a market cap of 8.8M. Regarding current trading prices, HPCO is priced at $0.00, while TLPH trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas TLPH's P/E ratio is -0.98. In terms of profitability, HPCO's ROE is -3.60%, compared to TLPH's ROE of -1.29%. Regarding short-term risk, HPCO is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check TLPH's competition here
HPCO vs IMCC Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, IMCC has a market cap of 8.6M. Regarding current trading prices, HPCO is priced at $0.00, while IMCC trades at $2.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas IMCC's P/E ratio is -1.99. In terms of profitability, HPCO's ROE is -3.60%, compared to IMCC's ROE of -0.79%. Regarding short-term risk, HPCO is less volatile compared to IMCC. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check IMCC's competition here
HPCO vs YCBD Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, YCBD has a market cap of 8.3M. Regarding current trading prices, HPCO is priced at $0.00, while YCBD trades at $0.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas YCBD's P/E ratio is 0.01. In terms of profitability, HPCO's ROE is -3.60%, compared to YCBD's ROE of -0.01%. Regarding short-term risk, HPCO is less volatile compared to YCBD. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check YCBD's competition here
HPCO vs NLTX Comparison July 2025
HPCO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HPCO stands at 5.3K. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, HPCO is priced at $0.00, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HPCO currently has a P/E ratio of N/A, whereas NLTX's P/E ratio is -0.28. In terms of profitability, HPCO's ROE is -3.60%, compared to NLTX's ROE of -0.49%. Regarding short-term risk, HPCO is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for HPCO.Check NLTX's competition here